Broth microdilution – mycolab.ai

Antibacterial and Antifungal Activity and Acute Toxicity of Crude Extracts From the Wild Edible Mushrooms Cantharellus veraecrucis, Cantharellus violaceovinosus, and Turbinellus floccosus

mycolabadmin

Researchers tested extracts from three wild edible mushroom species found in Mexican forests for their ability to fight harmful bacteria and fungi. The extracts showed promise against disease-causing microorganisms, with one species particularly effective against agricultural plant pathogens. While the extracts showed moderate toxicity at high doses, the results suggest these mushrooms could be developed into natural pesticides or medicines.

Clinical Isolate of Candida tropicalis from a Patient in North Carolina: Identification, Whole-Genome Sequence Analysis, and Anticandidal Activity of Ganoderma lucidum

mycolabadmin

Researchers in North Carolina identified a drug-resistant yeast infection (Candida tropicalis) from a hospital patient and tested whether extracts from reishi mushrooms (Ganoderma lucidum) could kill it. Using genetic analysis, they found mutations in the yeast that help it resist antifungal drugs. All three types of mushroom extracts tested successfully stopped the yeast’s growth and damaged its cells, suggesting that reishi mushrooms could be a promising natural treatment option for hard-to-treat candida infections.

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

This study examined Candida yeast infections in urine samples from hospitalized patients in Iran. Researchers identified seven different Candida species using a specialized PCR test and tested how well they responded to three antifungal medications. They found that while Candida albicans was most common, other species showed much higher resistance to fluconazole treatment. The findings highlight the importance of proper species identification for choosing the right treatment.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against dangerous fungal infections caused by Aspergillus species. The drug works by removing important minerals like zinc that these fungi need to survive. Testing showed nitroxoline was very effective against these fungi, even against strains that had developed resistance to modern antifungal drugs. This suggests nitroxoline could potentially be repurposed as a new treatment option for serious fungal infections.

Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods

mycolabadmin

Researchers compared three different laboratory methods for testing how well antifungal drugs work against common yeast infections. They tested 22 different yeast strains including Candida species using CLSI, EUCAST, and Sensititre YeastOne methods. The methods showed strong agreement overall, but some newer antifungal drugs like ibrexafungerp showed more variation between methods. The findings suggest these methods are reliable for guiding treatment decisions, but further standardization is needed for newer drugs.

Evaluation of the Cytotoxicity and Antifungal Efficacy of Crocus sativus (saffron) Petals on Clinical Isolates of Candida albicans

mycolabadmin

Researchers tested saffron petals as a natural antifungal treatment against Candida albicans, a common fungal infection. While the saffron extract was less potent than the standard drug fluconazole, it showed promise as a safer alternative with minimal toxicity to human cells. The findings suggest saffron petals could be a cost-effective herbal option for treating fungal infections, especially as resistance to conventional antifungals increases.

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

Researchers studied fungal infections in urine samples from hospitalized patients and found that while the common yeast Candida albicans was most prevalent, other Candida species were increasingly resistant to antifungal medications. Using advanced genetic testing methods, they identified seven different Candida species and tested their resistance to three common antifungal drugs. The findings highlight the growing problem of drug-resistant fungal infections and the need for better diagnostic tools to identify which species is causing infection so appropriate treatment can be selected.

Emergence of resistant dermatophytosis caused by Trichophyton indotineae: First case series in Thailand

mycolabadmin

Doctors in Thailand have identified a new drug-resistant fungal infection caused by Trichophyton indotineae, a fungus that doesn’t respond to common antifungal medication terbinafine. Five patients were diagnosed with this resistant skin infection that caused rashes on various body parts and failed to improve with standard treatments. The research shows that a simple urease test can help doctors quickly identify this resistant fungus, and a different drug called itraconazole appears to work better for treatment. This is the first time this resistant fungus has been confirmed in Thailand, suggesting it is spreading globally.

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

Researchers studied yeast infections in urine from hospitalized patients using advanced molecular testing. They found that while Candida albicans was most common, other yeast species were becoming more resistant to antifungal medications. The study used a 21-tube PCR test to identify different yeast species and tested which medications worked best against them. Results showed that newer yeast species were much more likely to resist commonly used antifungal drugs like fluconazole.

Antifungal efficacy of caffeic acid and nano-caffeic acid particles against candidiasis: an in vitro study

mycolabadmin

Researchers developed a nano-particle form of caffeic acid, a natural compound found in coffee and tea, to treat oral yeast infections (candidiasis). The nano-version showed better antifungal activity than regular caffeic acid, though not as strong as prescription antifungal drugs. Since it comes from plants with fewer side effects, it could offer an alternative treatment option for patients with candidiasis.

Research Keyword: Broth microdilution